Yaron Rotman, M.D., M.Sc.

Investigator

Liver Energy and Metabolism Section, Liver Diseases Branch

NIDDK

Building 10, Room 10N248C
10 Center Dr
Bethesda, MD 20814

+1 301 451 6553

rotmany@niddk.nih.gov

Research Topics

My ultimate goal is to increase understanding of the pathophysiology of fatty liver disease to allow for development of better treatment options.

Current Research

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disorder in the western world and is closely associated with metabolic syndrome, insulin resistance, and obesity.  My main interest is in understanding the disease pathophysiology and through it, normal liver physiology.  My studies focus on understanding the genetic aspects of fatty liver disease, its pathogenesis, the mechanisms of action of various treatment options, and the prediction of response to treatment.

Applying our Research

Non-alcoholic fatty liver disease is an extremely common disorder (affecting 30 percent of Americans) but currently has no approved therapy.  Better understanding of the mechanisms of disease may allow for identification of druggable targets, better selection of patients for treatment, and early prediction of treatment response, with the overall effect of preventing death and suffering associated with the disease.

Need for Further Study

We need a better understanding of the mechanisms that cause some individuals to accumulate fat in the liver during caloric excess, while others are protected.  Similarly, it is unclear why some individuals will develop liver injury and progressive disease after accumulating fat in their liver, while others maintain a relatively benign course.  Finally, better treatment options are needed.

Biography

  • Clinical Research Fellow, Liver Disease Branch, NIDDK, 2006-2009
  • Gastroenterology and Hepatology Fellowship, Rabin Medical Center, 2003-2006
  • Internal Medicine Residency, Rabin Medical Center, 2000-20003
  • M.D., Hebrew University Hadassah Medical School, 2000
  • M.Sc., Hebrew University Hadassah Medical School,2000

Selected Publications

  1. Ma Y, Belyaeva OV, Brown PM, Fujita K, Valles K, Karki S, de Boer YS, Koh C, Chen Y, Du X, Handelman SK, Chen V, Speliotes EK, Nestlerode C, Thomas E, Kleiner DE, Zmuda JM, Sanyal AJ, NASH CRN., Kedishvili NY, Liang TJ, Rotman Y. HSD17B13 is a Hepatic Retinol Dehydrogenase Associated with Histological Features of Non-Alcoholic Fatty Liver Disease. Hepatology. 2018.

  2. Takyar V, Nath A, Beri A, Gharib AM, Rotman Y. How healthy are the "Healthy volunteers"? Penetrance of NAFLD in the biomedical research volunteer pool. Hepatology. 2017;66(3):825-833.

  3. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, NASH CRN.. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology. 2010;52(3):894-903.

  4. Guber RD, Takyar V, Kokkinis A, Fox DA, Alao H, Kats I, Bakar D, Remaley AT, Hewitt SM, Kleiner DE, Liu CY, Hadigan C, Fischbeck KH, Rotman Y, Grunseich C. Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy. Neurology. 2017;89(24):2481-2490.

  5. Rotman Y, Sanyal AJ. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Gut. 2017;66(1):180-190.


This page was last updated on February 28th, 2019